Summary It has been suggested that sensitivity of ovarian carcinomas to cisplatin is in part related to an endogenous folate deficiency. In this work, we investigated whether overexpression of the folate-binding protein (FBP), a receptor involved in folate transport, might be associated with cisplatin sensitivity. The results obtained on a panel of ten ovarian carcinoma cell lines that overexpress different levels of the FBP showed a statistically significant relationship between FBP overexpression and cisplatin responsiveness, with the most sensitive cell lines expressing higher FBP levels on their membrane than the less sensitive ones. The relationship was observed both in cells growing in standard medium-containing high-folate concentrations (2.3 gM) and in cells adapted to growth in low-folate (20 nM) medium. Analysis of two cisplatin-resistant cell lines derived from the cisplatin-sensitive IGROV1 ovarian carcinoma cell line indicated that resistance was associated with a significant decrease in FBP expression. However, the receptor does not appear to be directly responsible for drug sensitivity per se as different cell lines transfected with FBP cDNA did not become more sensitive to the drug. Together, the data suggest the possible predictive value of FBP in ovarian carcinoma, as higher levels of expression can be indirectly but significantly associated with increased drug sensitivity.
Platinum-derived compounds have occupied a dominant place in cancer therapy, particularly for the treatment of ovarian malignancies (Rosenberg, 1985; Ozols, 1992) . Unfortunately, not all tumours are responsive, and initially sensitive tumours often become resistant in a short time Ozols et al, 1991) .
Various mechanisms have been proposed to contribute to cisplatin resistance, including altered drug accumulation (Loh et al, 1992; Nakagawa et al, 1993; Jekunen et al, 1994; Misawa et al, 1995) , enhanced drug detoxification by elevated metallothionein or glutathione levels (Andrews et al, 1987; Morrow et al, 1990; Tedeschi et al, 1990; Mistry et al, 1991) , enhanced DNA repair capability (Masuda et al, 1988; Eastman et al, 1988) or upregulation of specific biochemical pathways . Concerning, in particular, the last possibility, an association between cisplatin resistance and changes in folate metabolism has been observed. Indeed, cisplatin can stimulate endogenous methionine and folate metabolism (Gross et al, 1986; Shionoya et al, 1986; Scanlon et al, 1989a) . Enhanced 5,10-methylenetetrahydrofolate (5,10-methylene THF) and THF pools and enhanced gene expression of enzymes of the dTMP synthase cycle, which is the sole source of de novo dTMP, have been observed in drug-resistant cells (Scanlon et al, , 1989b Newman et al, 1988; Lu et al, 1988) . For example, A2780 human ovarian carcinoma cells selected for cisplatin resistance have elevated mRNA and enzyme activity for dTMP synthase cycle enzymes, such as dihydrofolate reductase, thymidylate synthase and thymidine kinase , thus suggesting that increased dTMP synthase activity might be required for the repair of cisplatin-induced DNA damage.
Previous reports have shown that the 38-KDa folate-binding protein (FBP) is overexpressed in a majority of non-mucinous ovarian carcinomas (Miotti et al, 1987; Campbell et al, 1991; Coney et al, 1991) and this folate receptor is directly involved in cellular internalization of folate compounds (Henderson, 1990; Antony, 1992) . Its increased expression in ovarian carcinomas, the cause of which has not yet been determined, raises intriguing questions about a possible altered folate metabolism in these tumour cells.
5-MethylTHF, the principal form of folate in serum, can be internalized into cells through the FBP but can also be obtained by the reduction of 5,10-methylene THF catalysed by methylene THF reductase. There is preliminary evidence to indicate that the methylene THF reductase gene is frequently deleted in ovarian carcinomas (Dall'Agnese et al, 1995) , raising the possibility that the cells overcome the decreased internal concentration of 5-methylTHF by overexpressing the external FBP receptor.
In the present study, we investigated whether the different levels of FBP expression found in ovarian carcinoma cell lines, which might reflect alterations in the folate metabolism, are predictive of tumour cell responsiveness to cisplatin treatment.
MATERIALS AND METHODS Cells and culture conditions
The following human ovarian carcinoma cell lines were used in this study: OVCAR3 , and were designated L-IGROV1, L-OVCA432, L-OVCAR4, L-SKOV3 and L-SW626. These cells were grown briefly in folate-free medium before cytotoxicity assay.
Transfected L-SKOV3, Chinese hamster ovary (CHO) and NIH/3T3 (Bottero et al, 1993) cells were maintained in L-RPMI, standard RPMI-1640 and standard Dulbecco's modified Eagle medium containing 9.2 gM folate (Boehringer-Mannheim, Germany), respectively, in the presence of 800 gg ml-' of geneticin G418 (GIBCO).
All media were supplemented with 5% or 10% heat-inactivated fetal calf serum (FCS), 2 mM L-glutamine, 100 units ml-1 penicillin and 100 gg ml' streptomycin. IGROV1/Pt 0.5 and IGROV1/Pt 1, two cisplatin-resistant sublines of IGROV 1, were kindly provided by Dr F Zunino (Istituto Nazionale Tumori, Milan). These sublines were selected by continuous exposure of cisplatin-sensitive IGROV1 cells to increasing drug concentrations and were maintained in medium containing 0.5 ,ug ml-' and 1 ,ug ml-' cisplatin (Platinex, Bristol Italiana, Sermoneta, Latina, Italy) .
Evaluation of cisplatin-induced cytotoxicity
A colorimetric assay based on 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was used to measure cytotoxicity. 
Vector construction and transfection
The human FBP cDNA, cloned into the pcDNAI/neo vector as described (Bottero et al, 1993) , was used to transfect CHO (Miotti et al, 1987) .
MAbs and indirect immunofluorescence assay
The following MAbs were used: anti-FBP MOv 18; MINT5 (Tosi et al, 1995) , which specifically detects the epidermal growth factor receptor (EGFR); MGR3 (Tagliabue et al, 1991) , produced against the HER-2/neu extracellular domain and W6/32 (ATCC, Rockville, MD, USA), detecting HLA class I molecules. Indirect immunofluorescence assay was carried out as described (Miotti et al, 1992) . Briefly, cells harvested by trypsinization were incubated with primary MAb (10 ,ug ml-' of purified MAbs or ascitic fluid diluted 1 :100) for 30 min at 37°C and, after two washings in PBS-5% FCS, incubated for an additional 30 min on ice with fluorescein-labelled goat anti-mouse Ig. Cells were washed twice, resuspended in cold PBS and analysed by FACScan. Cells incubated with fluoresceinated antibody only were included as a control for background staining. The immunofluorescence staining pattern of MOv18 on these cell lines ( Figure 3A ) indicated a cisplatin dose-dependent decrease in FBP expression levels; IGROV1/Pt 1 cells showed a single peak with a lower mean fluorescence than that of the parental cells, whereas IGROV1/Pt 0.5 cells showed two peaks, one which included about 30% of the cells, with a mean fluorescence value similar to that of the parental cells, and the other which was superimposible on the peak corresponding to the more resistant IGROV1/Pt 1 subline. Similar analyses using anti-HLA MAb W6/32 and anti-EGFR Mab MINT5 revealed no substantial differences between the parental and the variants in expression of these molecules ( Figure 3B and C respectively), whereas reactivity of MAb MGR3, which detects the extracellular domain of HER-2/neu, indicated that the level of protein was higher in the cisplatin-resistant variants than in the parental cells ( Figure 3D ). To examine whether cisplatin sensitivity is a direct consequence of FBP overexpression, both parameters were evaluated in NIH/3T3, CHO and L-SKOV3 cells transfected with a recombinant plasmid vector containing FBP cDNA (Table) . Transfected cells expressed from 6 to 20 times more FBP on the membrane than cells transfected with the empty vector (mock transfected).
The IC50 values expected on the basis of FBP expression were extrapolated from the regression rate of each cell line (for FBP-t and MOCK-t L-SKOV3 cells, directly from the regression rate reported in Figure 2a 
DISCUSSION
Our studies reveal a correlation between FBP expression and cisplatin sensitivity in ovarian carcinoma cell lines, although the relationship between the two parameters is probably indirect as overexpression of the folate receptor on cells transfected with FBP cDNA did not increase the drug sensitivity. As drug resistance is associated with low FBP expression, cisplatin sensitivity of ovarian tumours might be an indirect consequence of the event that induces these cells to overexpress FBP.
The mechanism responsible for FBP overexpression in ovarian carcinomas remains unknown. No gene amplification has been found so far (Foulkes et al, 1993) , indicating that regulation of FBP is likely at the transcriptional level. There is evidence to suggest that the response to cisplatin might be dependent on folate deficiency (Branda et al, 1993) . A correlation has been observed between cisplatin cytotoxicity and the requirement for exogenous folate. In particular, it has been demonstrated that relatively resistant human carcinoma cell lines require lower exogenous concentrations of folinic acid for growth (Scanlon et al, 1989a) . Thus, a cell line that relies more on endogenous folate metabolism than on exogenous contributions may be less sensitive to the cytotoxic effects of cisplatin. Consequently, FBP overexpression might be British Journal of Cancer (1997) 76 (1), [77] [78] [79] [80] [81] [82] . Cancer Research Campaign 1997 FBP expression and cisplatin sensitivity 81 an external signal of an internal deficiency of the cell in the use of folates, and this deficiency might have relevance in the cellular response to cisplatin as increased levels of enzymes involved in dTMP cycle are needed for DNA repair.
In our experiments in which the ovarian carcinoma cell lines were cultured at high (2.3 gM) extracellular folate concentrations (Figures 1 and 2A) , folate presumably enters the cells by passive diffusion, independent of the level of FBP expression (Antony et al, 1989) . Because these culture conditions ensured adequate delivery of folate to all cell lines used, the differential cisplatin responsiveness cannot be attributed to different availability of endogenous folates but instead might reflect differences in the capacity to use them. FBP expression levels have been reported to be inversely regulated by the extra-and intracellular folate concentration (Kamen et al, 1986; Kane et al, 1988) but, in our hands, only one (L-SKOV3) out of five ovarian carcinoma cell lines tested showed FBP up-modulation when adapted at physiological folate concentrations (20 nM) . In the same study, all the cell lines showed a marked decrease in endogenous folates compared with cells grown in standard medium (2.3 ,UM), and the amount of total folate in the cells was in general directly proportional to the level of membrane FBP expression, consistent with the concept that intracellular folate content is maintained primarily by FBP in low-folate cultured cells (Matsue et al, 1992 (Table) . These data support the notion that it is not FBP expression levels per se that underlie the cell response to cisplatin. However, the possibility exists that overexpression of FBP in plasma membrane of transfected cells reduced uptake of cisplatin, thus reducing the sensitivity of the cell lines to the drug.
Our analysis of the two cisplatin-resistant variants of IGROV1 cells confirms the inverse relationship between the degree of resistance and the number of FBP receptors ( Figure 3A ). This finding suggests that cisplatin treatment selects for cells that require only minimal FBP expression on the membrane for survival. This decreased FBP expression appears to be specific as other markers ( Figure 3B , C and D) remained essentially unchanged or increased compared with parental cells. It has to be noted that the increased expression of HER-2/neu on resistant cells is consistent with previous observations, suggesting the cisplatin resistance of HER-2/neu-positive tumours in vivo (Berchunck et al, 1990) . Thus, the in vitro selection procedure appears to result in cisplatin-resistant cells that reflect the in vivo situation.
The results of our study suggest the potential interest of FBP expression as a predictive factor in the outcome of ovarian carcinoma treatment with cisplatin, as higher levels of expression were significantly associated with more effective drug responsiveness. In addition, the data on the IGROVI-derived cisplatin-resistant cell lines suggest that cisplatin therapy can select for subpopulations of intrinsically drug-resistant tumour cells characterized by a lower FBP expression than the original tumour.
